Table 4

Comparison of COVID-19 positive ST-segment elevation myocardial infarction (STEMI) versus COVID-19 negative STEMI: procedural characteristics and clinical endpoints

COVID-19 positive
(n=46)
COVID-19 negative
(n=302)
P valueOR (95% CI)
Procedural characteristics
 Lesions treated1 (1–1)1 (1–1)0.44
 Vessels treated1 (1–1)1 (1–1)0.53
 Stents1 (1–2)1 (1–2)0.99
 Total length of stent (mm)38 (24–48)28 (20–38)0.012*
 Widest balloon (mm)3.5 (2.5–3.75)3.5 (3–4)0.14
 Cardiogenic shock6 (13%)41 (13.6%)0.920.95 (0.40 to 2.30)
 Gp2b3a inhibitor use26 (56.5%)117 (38.7%)0.022*2.06 (1.12 to 3.87)
 Thrombus aspiration use14 (30.4%)54 (17.9%)0.046*2.01 (0.99 to 4.05)
 TIMI flow <3 at end of case9 (19.6%)24 (8%)0.012*2.82 (1.16 to 6.45)
Clinical endpoints
 ICU admission15 (32.6%)28 (9.3%)<0.001*5.74 (2.24 to 9.89)
 Length of stay (days)4 (3–9)3 (2–4)<0.001*
 In-hospital mortality10 (21.7%)28 (9.3%)0.012*2.72 (1.25 to 5.82)
  • Procedural characteristics and clinical endpoints of patients with STEMI and concurrent COVID-19 and those without COVID-19 admitted during the study periods in 2020.

  • ICU, intensive care unit; TIMI, thrombolysis in myocardial infarction.